News | May 14, 2012

Benefit Shown for Automated Sensor-Based CRT Optimization in Heart Failure Patients

Data show significant improvement in heart failure patients’ response to cardiac resynchronization therapy with Sorin’s SonR


May 12, 2012 — Sorin Group announced at the Heart Rhythm Society (HRS) annual scientific sessions, the publication of the CLEAR study results in Europace (May 1, 2012, doi:10.1093/europace/eus059). The study demonstrates the clinical benefit of the SonR sensor based cardiac resynchronization therapy (CRT) optimization system in heart failure (HF) patients.

SonR is the first and only system to provide weekly automatic optimization during patient’s daily activities as an alternative to in-clinic manual echocardiography-based device settings. The unique SonR system consists of a dedicated sensor embedded in the tip of a pacing lead implanted with the CRT device. The sensor’s advanced technology allows direct measurement of real-time cardiac contractility and uses this hemodynamic signal to optimize the device’s parameters for each individual patient at rest and exercise.

The CLEAR clinical study, a prospective, multicenter, single-blind, randomized study conducted in 51 centers in eight European countries enrolled 238 patients with severe HF (New York Heart Association [NYHA] functional class III and IV and a left ventricular ejection fraction [LVEF] less than 35 percent). Study results at one year showed that with SonR’s regular automatic optimization of the device’s atrio-ventricular and inter-ventricular delays, 76 percent of patients were classified as improved, compared with 62 percent in the group of patients with standard CRT programming (p=0.0285).

“The publication of the CLEAR study is a remarkable milestone in the treatment of heart failure patients indicated for CRT,” said Philippe Ritter, M.D. University Hospital of Bordeaux, France and principal investigator of the CLEAR clinical trial. “The regular automatic optimization provided by SonR demonstrates significant increase in the proportion of heart failure patients improving with this therapy. It is the first time a device-based algorithm has demonstrated the ability to improve patient outcomes in a prospective, randomized trial. CRT optimization is usually performed in non-responder patients through an expensive, complex and time-consuming echocardiographic procedure. The SonR system optimization is automatic, individualized and performed on a regular basis by the device in all patients. It has the potential to reduce the number of echocardiographic procedures and its related costs.”

“We are very satisfied with the results of the prospective, randomized CLEAR trial which demonstrates that the SonR system provides unique clinical benefit for CRT patients. These results clearly highlight our ongoing commitment to innovation in the hemodynamic management of heart failure patients,” said Stefano Di Lullo, Sorin Group, president of the CRM business unit.

About SonR

The result of a 10-year clinical science program, the SonR sensor uniquely measures patient’s cardiac muscle vibrations related to the first heart sound. These real-time measurements are transmitted to the CRT-D device which uses them to determine the best settings for the patient. Every week, the system automatically optimizes to adapt to the patient’s changing condition. SonR measurements correspond to LVdP/dtmax, the gold standard for assessing left ventricular contractility, a key indicator of cardiac performance. SonR is the only CRT optimization system that automatically optimizes patients every week and importantly, while the patient is active, providing real-life optimization.

For more information:



Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init